Skip to main content
SpringerLink
Log in

Resource Utilization Associated with Irritable Bowel Syndrome in the United States: 1987–1997

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

This study uses national databases to examine the impact of irritable bowel syndrome (IBS) on resource utilization in the United States. Approximately 1.5–2.7 million physician visits (599–1043 per 100,000) yearly were related to IBS, with 45.3% seen by gastroenterologists, and 89% prescribed medications. Rates of physician visits by women were approximately 2.4–3.3 times higher than that for men. The average number of medication prescribed per visit was 1.83. Approximately 89% of the visits were prescribed with medications. The rate of hospitalization (5.1 per 100,000 in 1997) decreased by 60% and length of stay decreased from 5.5 to 3.1 days in the past decade. The average charges of IBS-related hospitalization were US$7,882. Our study found an apparent decreasing trend of IBS-related hospitalizations and no marked increase in office consultations in the past decade. However, a better case identification criterion is necessary to estimate the true disease burden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Thompson, Longstreth GF, Drossman DA, et al: Functional bowel disorders and functional abdominal pain. Gut 45(suppl 2):II43–II47, 1999

    PubMed  Google Scholar 

  2. Russo MW, Gaynes BN, Drossman DA: A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterology 29(4):339–343, 1999

    Google Scholar 

  3. Gershon MD. 5-HT (serotonin) physiology and related drugs. Curr Opin Gastroenterol 16:113–120, 2000

    Google Scholar 

  4. Baxendale A, Bountra C, Clayton N, et al: Irritable bowel syndrome as visceral hyperalgesia: implications for therapy? Curr Opin CPNS Invest Drugs 1:86–97, 1999

    Google Scholar 

  5. Harris MS: Irritable bowel syndrome: A cost-effective approach for primary care physicians. Postgrad Med 101(3):215–226, 1997

    PubMed  Google Scholar 

  6. Paterson WG, Thompson WG, Vanner SI, et al: Recommendations for the management of irritable bowel syndrome in family practice. Can Med Asso J 161(2):154–160, 1999

    Google Scholar 

  7. Sandler RS: Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 99:409–415, 1990

    PubMed  Google Scholar 

  8. Talley N, Zinsmeister A, Van Dyke C, Melton J: Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 101:927–934, 1991

    PubMed  Google Scholar 

  9. Drossman D, Zhiming Li, Andruzzi E, et al: US householder survey of functional gastrointestinal disorders; Prevalence, sociodemography, and health impact. Dig Dis Sci 38(9):1569–1580, 1993

    PubMed  Google Scholar 

  10. Camilleri M, Choi M: Irritable bowel syndrome. Ailment Pharmacol Ther 11:3–15, 1997

    Google Scholar 

  11. Agreus L: The epidemiology of functional gastrointestinal disorders. Eur J Surg Suppl 583:60–66, 1998

    Google Scholar 

  12. Everhart JE, Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 100:998–1005, 1991

    PubMed  Google Scholar 

  13. Farthing M: Irritable bowel syndrome: New pharmaceutical approaches to treatment, Ballieres Clin Gastroenterol 13:61–71, 1999

    Google Scholar 

  14. National Center of Health Statistics: National Ambulatory Medical Care Survey 1997. Public-use data file and documentation. ftp://ftp.cdc.gov/pub/Health Statistics/NCHS/ 1999

  15. 1997 National Disease and Therapeutic Index: IMS Health. Plymouth Meeting Pennsylvania

  16. National Center of Health Statistics: National Hospital Discharge Survey, 1997. Public-use data file and documentation. ftp://ftp.cdc.gov/pub/Health Statistics/NCHS/ 1999

  17. Department of Health and Human Services: International classification of diseases, Clinical modification, 9th rev., 5th ed. US Public Health Service, Health Care Financing Administration. 1994

  18. International Classification of Diseases, Clinical Modification, 9th rev., 5th ed. Salt Lake City, Utah, Medicode Publications, 1996

  19. SAS Institute: SAS Version 6.12, SAS Institute, Cary, North Carolina

  20. Lynn R, Friedman L: Current concepts: Irritable bowel syndrome. N Engl J Med 329:1940–1944, 1993

    PubMed  Google Scholar 

  21. Drossman D: Irritable bowel syndrome and sexual/physical abuse history. Eur J Gastroenterol Hepatol 9:327–330, 1997

    PubMed  Google Scholar 

  22. Bonis P, Norton R: The challenge of irritable bowel syndrome. Am Fam Physician 53:1229–1235, 1996

    PubMed  Google Scholar 

  23. Camilleri M, Choi MG: Clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 13(suppl 2):48–53, 1999

    PubMed  Google Scholar 

  24. Dixon-Woods M, Critchley S: Medical and lay views of irritable bowel syndrome. Fam Pract 17:108–113, 2000

    PubMed  Google Scholar 

  25. Iezzoni L (ed): Risk adjustment for measuring healthcare outcomes. Chicago, Health Administration Press, 1997

    Google Scholar 

  26. Kozak LJ, Lawrence L: National hospital discharge survey: Annual summary, 1997. National Center for Health Statistics. Vital Health Stat 139:144, 1999

    Google Scholar 

  27. Inglehart JK: The American health care system—expenditures. N Engl J Med 340:70–76, 1999

    PubMed  Google Scholar 

  28. Talley NJ, Zinsmeister AR, Melton LJ: Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol. 142(1):76–83, 1995

    PubMed  Google Scholar 

  29. McFarland B: Comparing period prevalences with application to drug utilization. J Clin Epidemiol 49:473–482, 1996

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MEDTAP International Inc., Bethesda, Maryland, USA

    Ya-Chen Tina Shih

  2. Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA

    Victoria E. Barghout

  3. University of North Carolina, Chapel Hill, North Carolina, USA

    Robert S. Sandler

  4. Research Triangle Park, GlaxoSmithKline Inc., U.S. Medical Affairs Health Outcomes, North Carolina, USA

    Priti Jhingran, Suzanne Cook & David C. Gibbons

  5. Research Triangle Park, Strategic Outcomes Services of Care Science Inc., North Carolina, USA

    Medha Sasane

  6. Exponent Inc., Alexandria, Virginia, USA

    Michael Halpern

Authors
  1. Ya-Chen Tina Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victoria E. Barghout
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert S. Sandler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Priti Jhingran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Medha Sasane
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suzanne Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David C. Gibbons
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael Halpern
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shih, YC.T., Barghout, V.E., Sandler, R.S. et al. Resource Utilization Associated with Irritable Bowel Syndrome in the United States: 1987–1997. Dig Dis Sci 47, 1705–1715 (2002). https://doi.org/10.1023/A:1016471923384

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016471923384

Search

Navigation